OEL Fastrac Catalog

Please note, this OEL/ADE monograph also applies to zidovudine sodium (CAS RN 106060-86-0). Zidovudine is used to treat human immunodeficiency virus (HIV) infection and for the prevention of transmitting HIV from infected mother to infant during labor and delivery. Zidovudine, a structural analog of thymidine, is phosphorylated intracellularly by cellular thymidine kinase to zidovudine monophosphate. The monophosphate is converted to the diphosphate by cellular thymidylate kinase and is further converted to the triphosphate by other cellular enzymes. Zidovudine triphosphate competes with the natural substrate, thymidine triphosphate, for incorporation into growing chains of viral RNA-dependent DNA polymerase (reverse transcriptase), thereby inhibiting viral DNA replication. Once incorporated, zidovudine triphosphate also prematurely terminates the growing DNA chain since the 3′-azido group prevents further 5′ to 3′ phosphodiester linkages. Zidovudine has a 100- to 300-fold greater affinity for inhibiting HIV reverse transcriptase than it does for inhibiting human DNA polymerase.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Zidovudine, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.